Importantly, our analyses exposed a subtype of primary prostate cancer characterized by divergent AR (low) and MYC (high) transcriptional signatures that are predisposed to fail standard-of-care therapies and progress to the mCRPC stage (Fig. 5). The gene discussed is MYC; the disease is Familial prostate cancer.